Hosted on MSN1mon
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
Novartis2d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
WRIC27d
FDA approves first opioid-free painkiller in over two decades
RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.
FDA approves new, non-opioid painkiller Journavx
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain ...
Alnylam's Amvuttra Gets Approval for Expanded Indication From FDA
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.
Business Wire1mon
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi ® (risdiplam) tablet for people living with spinal muscular ...